http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
악성 흉막액에 대한 흉막강내 OK - 432 주입의 치료 효과
방영주(Yung Jue Bang),서철원(Chol Won Seo),이재훈(Jae Hoon Lee),신동복(Dong Bok Shin),강윤구(Yoon Koo Kang),박근칠(Keun Chil Park),김노경(Noe Kyeong Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.4
N/A OK-432 has been shown to have antitumor activity in cancer patients, and intrapleural injection of OK-432 had also been shown to cause reduction or disappearance of pleural effusions and/or tumor cells in pleural effusions of cancer patients. Forty patients with malignant pleural effusions were treated with intrapleural administration of OK-432. Their age ranged from 20 to 80 years with a median of 56 years, and the male to female ratio was 24:16. Primary tumor sites were lung in 30 patients, stomach in 3, colon in 1, ovary in 1, and 5 patients had adenocarcinoma of unknown primary site. Cytologic examinations of pleural fluid were positive in 30 patients, and 10 patients without cytologic proof had exudative effusions with elevated levels of carcinoembryonic antigen. Their performance status was ECOG grade 1 in 9, 2 in 18, and 3 in 13 patients. One to three courses of intrapleural injection of OK-432 were tried weekly (mean 1.3 courses) without any concomitant anticancer treatment. The responses were categorized as objective response or failure. Seven patients were not evaluable for response because of early death without pleural effusion in two, protocol violation in one, and lost to follow-up in four. Twenty-four patients (72.7%) achieved objective responses among 33 evaluable patients. Response duration ranged from 4+ to 59 weeks with a median of 52 weeks. Common toxicities included fever and chill (38/52 courses), and pleuritic chest pain (24/52), but those symptoms were tolerable. These results show that intrapleural administration of OK-432 appears to be effective in the control of malignant pleural effusions with acceptable toxicity.
악성종양에서 골수면역신티그라피를 이용한 골수전이의 평가 : $^{99m}Tc$-MDP 뼈스캔과의 비교
이경한,최창운,방영주,정준기,정홍근,이명철,김병국,김노경,고창순,Lee, Kyung-Han,Choi, Chang-Woon,Bang, Yung-Jue,Chung, Jun-Key,Chung, Hong-Keun,Lee, Myoung-Chul,Kim, Byoung-Kook,Kim, Noe-Kyeong,Koh, Chang-Soon 대한핵의학회 1994 핵의학 분자영상 Vol.28 No.1
Although bone scan is a highly sensitive test for detecting bone metastasis, its findings are often limited in specificity and cannot be used for assessing the bone marrow. Bone marrow scintigraphy may provide useful information but previous experience with radiolabelled colloid has been disappointing. Recently, $^{99m}Tc$ labeled anti-granulocyte monoclonal antibody (anti-NCA-95 MAb) has been introduced as a new bone marrow imaging agent. To evaluate the usefulness of $^{99m}Tc$ anti-NCA MAb bone marrow scans for detecting skeletal metastasis, bone marrow scans of 44 malignant tumor patients were evaluated and compared with bone scan findings. Bone scan showed abnormal lesions in 26(59%) cases, and 18 of these patients also had an abnormal bone marrow scan. Seven of the 8 patients who had normal bone marrow scan despite bone scan lesions were confirmed to be free from metastasis. There was one case with a marrow defect despite normal bone scan but the presence of metastasis was not determined due to loss of follow up. Bone scan demonstrated a total of 64 lesions while bone marrow scan showed 38 lesions. Fifty percent (32/64) of the bone scan lesions had matching marrow defects while the remaining 50% did not. Most of these non matched lesions were suggested to be nonspecific lesions such as rib fractures or degenerative change. Meanwhile bone marrow scan was able to detect 6 new lesions not detected by bone scan, bit metastasis in each lesion was not confirmed. Bone marrow scan was also helpful in assessing equivocal bone scan lesions to be of metastatic nature in 10 patients by demonstrating a matched marrow defect. Thus $^{99m}Tc$ anti-NCA MAb bone marrow scan can help exclude metastasis in patients with nonspecific bone scan lesions and may be able to detect metastatic lesions not seen with bone scan. It appears useful as a complementary study to bone scan in evaluating malignant tumor patients.
The Result of Radiotherapy in Esophageal Cancer
박찬일,최은경,정웅기,방영주,김노경,Park, Charn-Il,Choi, Eun-Kyung,Chung, Woong-Ki,Bang, Yung-Jue,Kim, Noe-Kyeong The Korean Society for Radiation Oncology 1988 Radiation Oncology Journal Vol.6 No.2
1979년 3월부터 1986년 8월까지 식도의 편평상피암으로 진단되어 서울대학교병원 치료방사선과에서 방사선치료를 받은 177명중 근치적 방사선 치료를 시행한 152명을 대상으로 후향성 분석을 시행하여 다음과 같은 결과를 얻었다. $80\%$이상의 환자에서 관해를 보였으며, 이중 완전관해는 $22\%$, 부분 관해는 $63\%$이었다. 전체 환자의 2년, 5년 생존율은 각각 $22.9\%,\; 13.3\%$이었으며 식도암의 위치, 크기, 병기 그리고 관해 정도에 따라 생존율에 차이가 있었다. 식도 촬영상 5cm 이하$(17\%)$ 또는 식도의 상부 1/3에 종양이 있는 경우$(25.6\%)$에 가장 좋은 5년 생존율을 보였다. 관해 정도에 따른 생존율은 완전관해를 보인 경우의 5년 생존율이 $34.3\%$인 반면 반응이 없던 경우는 $0\%$이었다 During the period between March 1979 and August 1986, 177 patients with carcinoma of the esophagus were treated with radiotherapy in the Department of Therapeutic Radiology, SNUH. Among these, 25 patients who had incomplete treatment were excluded. So a retrospective analysis was undertaken of 152 patients who were treated by curative radiotherapy. More than $80\%$ showed response: Complete remission $(22\%)$, partial remission $(63\%)$ and no response $(15\%)$. The overall two-year and five-year actuarial survival rate were $22.9\%\;and\;13.3\%$ respectively. Prognostic factor was analyzed by its site, size, T stage, and tumor response. Patients with the best five-year survival rate were those who had the tumor no more than 5cm in length $(17\%)$ or confined to the upper third of the esophagus $(20.6\%)$. Complete responders had $34.3\%$ of 5-year actuarial survival, but no responders had $0\%$ of survival.
Klinefelter 씨 증후군과 연관된 원발성 종격동 생식세포암 1 예
서창인(Chang In Suh),배현주(Hyun Jue Bae),서철원(Cheol Won Suh),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.4
N/A Klinefelter's syndrome is the most common cause of primary testicular failure and is defined by the spectrum of phenotypic features resulting from a sex chromosome complement that includes 2 or more X chromosomes and 1 or more X chromosomes. Several reports suggest that patients with klinefelter's syndrome are predisposed to the development of a nonseminomatous germ cell tumor in the mediastinum, We recently experienced a 26-year-old man with klinefelter's syndrome and primary mediastinal embryonal cell carcinoma, who was treated with combination chemotherapy and resection of the residual tumor.
수술이 불가능한 전이성 또는 국소 진행성 위암 환자에서 선행화학요법의 효과
정유승,박도중,이혁준,김세형,한준구,김태유,방영주,허대석,김노경,김우호,양한광,이건욱,최국진,Chung Yoo-Seung,Park Do Joong,Lee Hyuk-Joon,Kim Se Hyung,Han Joon Koo,Kim Tae-You,Bang Yung-Jue,Heo Dae Seog,Kim No Kyung,Kim Woo Ho,Yang Han-Kwang 대한위암학회 2004 대한위암학회지 Vol.4 No.1
Purpose: The purpose of this study was to evaluate the treatment result of surgical resection after preoperative chemotherapy in inoperable gastric cancer patients. Materials and Methods: We analyzed 18 gastric cancer patients who underwent gastric resection after preoperative chemotherapy because they showed some clinical response to chemotherapy (15 with distant metastasis and 3 with locally advanced lesions). The mean postoperative follow-up period was $15.3\pm15.5$ ($1\∼56$) months. Results: In 15 patients with distant metastasis, 2 ($13.3\%$) showed complete response (CR), 10 ($66.7\%$) partial response (PR), 2 ($13.3\%$) stable disease (SD), and 1 ($6.7\%$) progressive disease (PD). The clinical response rate was $80.0\%$ Five subtotal gastrectomies, 4 total gastrectomies, and 6 extended total gastrectomies were performed. Two cases of CR were alive without recurrence for 4 and 26 months, respectively. Mean survival period in PR case was 37.7 months, but 2 cases of SD and 1 case of PD died after 11.7, 17.9, and 0.9 months, respectively. Postoperative survival was significantly associated with the response to chemotherapy (P<0.01). The mean survival period of the 10 patients with a complete resection was 44.1 months, which was significantly better than that of the 5 patients with an incomplete resection (9.8 months, P=0.03). Among 3 patients with locally advanced gastric cancer, 2 cases showed PR to chemotherapy, and complete resection was possible only by gastrectomy for those patients. Conclusion: In some selected cases, surgical resection was achievable after preoperative chemotherapy for patients with inoperable metastatic or locally advanced gastric cancer.
종양 표지 인자로서 혈장 Transforming Growth Factor-β1에 대한 연구
신훈,임창기,최인영,이두연,노동영,류민희,이효석,방영주,박종섭,진승원,Shin, Hoon,Lim, Chang Ki,Choi, In Young,Lee, Doo Yun,Noh, Dong Yong,Ryu, Min Hee,Lee, Hyo Suk,Bang, Yung Jue,Park, Jong Sup,Jin, Seung Won 대한면역학회 2001 Immune Network Vol.1 No.2
Background : Many investigators have found transforming growth factor-${\beta}1$ (TGF-${\beta}1$) to be elevated in tumors. Changes in responsiveness to TGF-${\beta}1$ have been linked to malignant transformation, tumor progression and tumor regression. Many malignant cell lines of epithelial or hematopoietic origin are refractory to the antiproliferative effects of TGF-${\beta}1$. However, a little is known about the association of TGF-${\beta}1$ with progression of malignant tumor. Methods : In this study, we measured the plasma level of TGF-${\beta}1$ in various cancer patients and evaluated the utility of plasma TGF-${\beta}1$ as a possible tumor marker. Plasma TGF-${\beta}1$ levels were measured using enzyme-linked immunosorbent assay in cancer patients and normal controls. Carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) as tumor marker were compared with TGF-${\beta}1$ in the aspects of sensitivity and specificity. Results : The mean of plasma TGF-${\beta}1$ levels was $1.219{\pm}0.834ng/ml$ in normal controls, $5.491{\pm}3.598ng/ml$ in breast cancer, $12.670{\pm}10.386ng/ml$ in lung cancer, $5.747{\pm}3.228ng/ml$ in hepatocellular carcinoma and $10.854{\pm}7.996ng/ml$ in cervical cancer. In comparison with CEA and AFP, TGF-${\beta}1$ is more sensitive. Conclusion : We conclude that the high levels of TGF-${\beta}1$ are common in the plasma of cancer patients. These results suggest that the plasma TGF-${\beta}1$ level can be a potent tumor marker in various cancer patients.
다발성 골수종에 대한 Vincristine , Melphalan 및 Prednisone ( VMP ) 복합화학요법의 치료 효과
김태유(Tae You Kim),허대석(Dae Seog Heo),방영주(Yung Jue Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),김효진(Hyo Jin Kim) 대한내과학회 1993 대한내과학회지 Vol.45 No.1
N/A Background: The combination of melphalan and prednisone has been the standard therapy for multiple myeloma. However, owing to the emergence of the drug resistance, essentially most patients have relapse or progrssion during chemotherapy. Vincristine was reported to be albe to prevent the development of the resistance to melphalan. Methods: Sixty two patients with multiple myeloma were treated with a combination chemotherapy of vincristine, melphalan and prednisone (VMF). The regimen consists of vincristine 0.03 mg/kg i.v. (day 1), melphalan 0,1 mg/kg p.o. (day 1-7) and prednisone 1mg/kg p.o. (day 1-7), which was repeated every four weeks. Results: Among 51 evaluable patients, 29 patients (56%) achieved objective responses. The median duration of response was 15 months. The median time to progression of overall patients was 11 months. The factors influencing response were age (p<0.04) and performance status (p<0.03). The overall median surivival was 36 months. The single most important factor associated with prolonged survival was the responsiveness to remission induction chemotherapy (p<0.001). Leukopenia was observed in 42% and thrombocytopenia in 2%. Neurotoxicity due to vincristine was found in 5.2% of the patients. Conclusions: The VMP regimen was associated with relatively high response rate and well tolerted, producing only mild bone marrow suppression and neuratoxicity. This result shows that VMP combination chemotherapy is an effective treatment regimen for multiple myeloma.